CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 68 enrolled
Drug / intervention
CD34+ Hematopoietic Progenitor Cells (HSPC) +3 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01660607
NCT01660607Phase 2Completed
CompareCT.gov

Phase 1-2 Trial for Patients With Advanced Hematologic Malignancies Undergoing Myeloablative Allogeneic HCT With a T-cell Depleted Graft With Infusion of Conventional T-cells and Regulatory T-cells

Stanford University·interventional·Posted Aug 8, 2012·Updated Aug 19, 2025

In Brief

A Phase 2 clinical trial evaluating CD34+ Hematopoietic Progenitor Cells (HSPC), Regulatory T-Cells (Treg), and 2 other interventions for Myeloid Leukemia, Chronic and 8 related conditions. Completed, enrolled 68 participants across 1 site.

Detailed Summary

This study looks at giving specific types of immune cells, called regulatory T cells and conventional T cells, to patients with blood cancers who are receiving a stem cell transplant. These cells are added back to help the immune system recover and reduce complications after the transplant.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMyeloid Leukemia, Chronic, Acute Myelogenous Leukemia, Myelodysplastic Syndromes (MDS), Lymphoma, Non-Hodgkin, Acute Lymphoblastic Leukemia (ALL), Myeloproliferative Syndrome, Acute Myeloid Leukemia, Acute Leukemia, Chronic Myelogenous Leukemia
CountriesUnited States
CollaboratorsNational Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI)

Timeline

Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedAug 8, 2012
Enrollment StartFeb 9, 2012
Primary CompletionDec 20, 2023
TodayJul 2, 2026
Enrollment to primary: 11.9 yearsPosted 13.9 years ago

Interventions

CD34+ Hematopoietic Progenitor Cells (HSPC)biological

Purified CD34+ hematopoietic progenitor cells used in transplantation.

Regulatory T-Cells (Treg)biological

Highly purified CD4+CD25+CD127-FoxP3+ regulatory T cells to reduce graft-versus-host disease.

Conventional T-Cells (Tcon)biological

Conventional CD3+ T cells used for immune reconstitution and graft enhancement.

Myeloablative Conditioning Regimenprocedure

Chemotherapy or total body irradiation used before hematopoietic cell transplantation.